Introduction
Allogeneic stem cell transplantation (allo-SCT) is the treatment of choice for many hematological malignancies as well as for severe immunodeficiency. However, there are serious risks associated with this procedure. The main causes of patient mortality and morbidity after transplantation are relapse, graft-versus-host disease (GVHD), hepatic venoocclusive disease (VOD), and infections. 1, 2 Various complications occurring after allo-SCT are believed to be manifestations of systemic inflammatory response syndrome (SIRS). 3 SIRS is caused by hypercytokinemia with the excess production of proinflammatory cytokines. 4 Organ impairment in SIRS is believed to occur as a sequel to vascular endothelial damage. 5 It is generally recognized that cross-linking of the cytokine network plays an important role in the inflammatory processes. For example, a dysregulation of cytokine production may initiate and perpetuate tissue damage in those who undergo allo-SCT.
Vascular endothelial growth factor (VEGF) is a dimeric glycoprotein that increases the vascular permeability and induces the proliferation and migration of endothelial cells to form new blood vessels. 6, 7 The role of angiogenesis in sustaining an inflammatory response has only recently become evident. VEGF acts as a potent chemo-attractant for leukocytes into neovascularization site and induces endothelial cells to produce collagenase. VEGF has also been implicated in a variety of chronic inflammatory diseases, 8 and is intimately linked to the cytokine network because its expression is upregulated by a number of cytokines and growth factors. Moreover, a recent study reported an increased expression of cytochemokines, including MCP-1, IL-8, TNF-a and IL-1b, in peripheral blood monocytes treated with the placental growth factor, 9 which has a remarkably similar three-dimensional structure to VEGF. 10 VEGF might be one of principal factors regulating the immune reactions associated with acute and/or chronic GVHD. 11 This study examined the association between the serum levels of VEGF in the early stages after allo-SCT and the occurrence of transplant-related complications. The VEGF levels were prospectively measured in the pretransplantation and early post-transplantation period according to the rationale that VEGF might be a predictive marker for clinical events.
Materials and methods

Patients and transplant characteristics
Eighty-five allo-SCT patients were prospectively enrolled in our institute. There were 25 cases of acute myelogenous leukemia (AML), 18 cases of acute lymphoblastic leukemia (ALL), 15 cases of myelodysplastic syndrome (MDS), 16 cases of severe aplastic anemia (SAA), eight cases of chronic myelogenous leukemia (CML) and three cases of paroxysmal nocturnal hemoglobinuria (PNH) ( Table 1) . Of the 85 patients examined, 54 and 31 received transplants from related and unrelated donors, respectively. Seventythree patients were human leukocyte antigen (HLA) matched on all six antigens or eight allele loci. All patients except for those with SAA and PNH were defined as having advanced disease if they had AML and ALL other than the first complete remission (CR1), primary induction failure, acute leukemia from antecedent hematology disorder, MDS (not refractory anemia or refractory anemia with ringed sideroblasts) and CML not in the first chronic phase. All others were defined as having early disease: AML and ALL in CR1, MDS with refractory anemia or refractory anemia with ringed sideroblasts, and CML in the first chronic phase. The patients were treated with myeloablative (49/85, 57.6%) or reduced-intensity (36/85, 42.4%) Bone marrow (BM) and granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (PBMC) were the sources of stem cells in 50 (58.8%) and 28 patients (32.9%), respectively. Seven patients (8.3%) received BM þ PBMC as the stem cell source. 12 All patients received 300-450 mg of G-CSF from day þ 7 until the absolute neutrophil count (ANC) exceeded 3.0 Â 10 9 /l, and all patients were treated in HEPA-filtered rooms using standard reverse isolation procedures. All blood components were irradiated in order to prevent transfusion-related GVHD. Oral prophylactic antibiotics were administered to all the patients. As soon as a fever had developed, oral antibiotics were discontinued and broadspectrum i.v. antibiotics were administered.
GVHD prophylaxis and treatment
For GVHD prophylaxis, 51 patients (60%) received a combination of cyclosporin A (CsA) and methotrexate (MTX). The CsA was administered i.v. as a continuous infusion at a dose of 3 mg/kg from days À1 to þ 21. Thereafter, CsA was given orally at a total dose of 5 mg/kg/ day divided into two doses, to maintain a blood concentration of between 200 and 500 ng/ml. MTX was administered at 10 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11. FK-506 and MTX were used for GVHD prophylaxis in 29 patients (34.1%). The FK-506 was given i.v. as a continuous infusion at a dose of 0.03 mg/kg from days À1 to þ 21 and then orally at a total dose of 0.12 mg/kg/day divided into two doses to maintain a blood concentration between 10 and 20 ng/ml. 13 Five patients (5.9%) received either CsA or FK-506 with mycophenolate mofetil as the GVHD prophylaxis.
14 Acute GVHD was defined as that occurring before day þ 100 and was graded on a four-point scale (I indicates mild disease, and IV severe disease). 15 Chronic GVHD was defined as that occurring 100 days after transplantation and was classified as being either limited or extensive, as previously described. 16 Methylprednisolone was used at 4 mg/kg/day for 4-7 days with a gradual taper to treat acute GVHD grade XII. Skin, rectum, or liver biopsies were performed where indicated to confirm GVHD.
Definition of other complications
Fever was defined as a body temperature X38.31C for at least 2 consecutive days. A clinically defined infection (CDI) was determined if the fever was accompanied by the appropriate clinical findings including pulmonary infiltration, inflammation of the skin or soft tissue. 17 Hepatic venoocclusive disease (VOD) was diagnosed according to the presence of hyperbilirubinemia (43.0 mg/dl), weight gain (42.5% of the initial weight) and right upper quadrant pain with or without the presence of hepatomegaly. 18 Thrombotic microangiopathy (TM) was defined as evidence of microangiopathic hemolysis with schistocytes on the peripheral blood smear and elevated serum LDH levels. 19 Cytomegalovirus (CMV) antigenemia was diagnosed by immunohistochemical staining using the monoclonal antibodies against the CMV pp65 protein.
Antigenemia-guided, risk-adapted preemptive therapy was performed with the aim of preventing CMV disease. 20 Blood sample collection and cytokine level determination Blood samples were collected on day 0 (before the stem cell infusion) as well as on days þ 7 and þ 14 after the transplant. The blood was centrifuged for 10 min at 2500 r.p.m., aliquots of the serum were stored at À201C until needed. The serum VEGF levels were measured using a sandwich enzyme-linked immunosorbent assay according to the standard protocols (R&D, Minneapolis, MN, USA). Each sample was tested in duplicate and the average is reported as a picogram per milliliter (pg/ml). The sensitivity of detection ranged from 1 to 1000 pg/ml.
Statistical methods
Cluster analysis was performed using a logarithmically transformed concentration of VEGF on days þ 7 and þ 14 with the highest value being used to categorize the patients according to the VEGF level. Two levels of VEGF were classified based on cluster analysis, a low and a high group. By utilizing the analysis, the degree of association can be strong between members of the same cluster and weak between members of different clusters. The Mann-Whitney test was used to compare the continuous variables. The association between the categorical variables was examined using either a w 2 or Fisher's exact test. The nonrelapse mortality (NRM) was defined as death due to any reason except for relapse before day þ 365 after the transplant. Log-rank analysis was used to examine the relationship between the VEGF levels and the cumulative incidence of NRM. The occurrence of major transplant-related mortality, such as severe acute GVHD, hepatic VOD, TM, CDI and chronic GVHD were then analyzed. The clinical data were collected from the hospital records. The course of the VEGF levels from the date of transplantation through to the second week after transplantation was tested using repeated measures ANOVA. Pair-wise comparisons were carried out for the two defined VEGF groups for the baseline level on the day of transplantation and for the slope over this period. A Cox or logistic regression model was also constructed to assess the relationships between NRM and the VEGF levels, in order to substantiate the findings in the presence of potential confounding factors. The covariates in the models were gender, age, disease status, graft source, donor type (related or unrelated transplant), transplantation type (myeloablative and reduced-intensity), the match of the HLA allele and the transplant outcome. A professional statistician was involved in the analysis. The patients were followed up until death, the last follow-up date or the end point of study, 31 December 2005.
Results
VEGF trajectory and transplant characteristics
The serum VEGF levels were measured before transplantation and on days 0, þ 7 and þ 14 after the transplant. On day þ 7, the VEGF levels decreased significantly compared with those measured on day 0 and recovered on day þ 14 (mean7s.e.: day 0, 94.4716.6 pg/ml; day þ 7, 54.8713.3 pg/ml, Po0.001 compared to day 0; day þ 14, 93.3714.5 pg/ml). The patients were categorized into two groups based on cluster analysis of the highest VEGF levels from the first week through to the second weeks after transplantation: those with low (n ¼ 56) and high (n ¼ 29) levels of circulating VEGF (Figure 1) . The median concentrations of the VEGF cytokine in these two groups were 31 pg/ml (range, 2-70 pg/ml) and 229 pg/ml (range, 86-967 pg/ml), respectively. The median levels of log-transformed VEGF were 3.2 pg/ml and 5.3 pg/ml, respectively. Figure 2 shows the log-transformed VEGF levels from the pretransplantation period through to two weeks after the transplant according to the defined VEGF groupings. As shown in the figure, the VEGF levels were significantly higher in the high VEGF group during the pretransplantation period. In addition, there was a significant difference in the slopes of the VEGF levels from the pretransplantation date through to day þ 14 between the 2 groups, as revealed by repeated-measures ANOVA (low versus high, Po0.001). The effect of low or high VEGF levels from the pretransplantation period was maintained throughout the patients' clinical course despite the disease status, graft source, donor type, transplantation type and match of the HLA allele, all of which were not significantly associated with the trajectory. The median follow-up time for this cohort, calculated as the time from the transplant to the final collection, was 380 days (range, 34-585). Table 1 shows the patients and transplant characteristics for the entire group as well as for the two distinct groups. The pretransplant variables, which are known to potentially affect the transplant-related mortality were comparable between the low and high VEGF groups. There were no significant differences in terms of age, gender, disease status, disease type, donor type, graft source, transplantation type, match of the HLA alleles and number of cells infused. Table 2 shows the transplant outcome of the two groups. The time from the transplant to an ANC 40.5 Â 10 9 /l was similar in the low and high VEGF groups (mean7s.e.: 14.670.5 days vs 13.470.9 days, P ¼ 0.204). Surprisingly, the time to a platelet count 420 Â 10 9 /l was significantly longer in the patients with low VEGF levels than in those VEGF correlates with reduced severity of acute GVHD C-K Min et al with high VEGF levels (mean7s.e.: 26.573.6 days vs 16.271.7 days, P ¼ 0.011). The incidence of post-transplant complications such as CDI, hepatic VOD, TM, a CMV infection and the occurrence of chronic GVHD was similar in the two groups. The log-rank tests comparing the NRM between the two groups indicated the 1-year probability of NRM in patients with low VEGF levels to be 22.5% compared with 3.5% for those with high VEGF levels (hazard ratio ¼ 7.332, 95% CI, 1.179-11.093; P ¼ 0.024, Figure 3 ) Overall, 29 patients (34.1%) developed acute GVHD, including six with grade I, 15 with grade II, six with grade III and two with grade IV. The incidence of acute GVHDXgrade II was similar in the low and high VEGF groups (P ¼ 0.175). However, there was a significant correlation between low VEGF levels and the occurrence of severe acute GVHD including grade III-IV (P ¼ 0.029). Figure 4 shows a comparison of the log-transformed levels of the VEGF concentration, which were obtained 2 weeks after the transplant with respect to the severity of acute GVHD. Patients with acute GVHDXgrade III (n ¼ 8; mean7s.e.: 2.2670.49 pg/ml) showed a marked decrease in the post-transplant VEGF levels compared with those with either grade I-II acute GVHD (n ¼ 21; mean7s.e.: 4.4970.25 pg/ml) or no acute GVHD (n ¼ 56; mean7s.e.: 3.6870.19 pg/ml) (P ¼ 0.029 and 0.001, respectively; acute GVHDXgrade III as the reference).
VEGF trajectory and transplant outcome
Analysis of risk factors for patient NRM
Together with the VEGF cluster, several factors that are likely to have some influence on a patient's survival after allo-SCT were tested to determine if they increased the risk of developing transplant-related complications. These included age, gender, disease status at the time of the transplant, donor type, graft source, transplantation type, match of the HLA alleles, number of cells infused, ANC or platelet recovery, a CMV infection, CDI, hepatic VOD, TM and the occurrence of severe acute GVHDXgrade III. Table 3 shows the results of a univariate analysis using the Cox regression model. The disease status, platelet engraftment, CDI, hepatic VOD, TM and the occurrence of acute GVHD greater than or equal to either grade II or III were significantly associated with the occurrence of NRM. The VEGF cluster exhibited a marginally significant impact on Figure 4 Means of the log-transformed VEGF levels on day þ 14 after transplant were compared according to the severity of acute GVHD. The levels in the patients with acute GVHDXgrade III (n ¼ 8) were significantly lower compared to those with acute GVHD gradepII (n ¼ 21) or without acute GVHD (n ¼ 56) ( w P ¼ 0.029 and 0.001, respectively).
NRM (P ¼ 0.056) and appeared to be a new parameter for assessing the risk of a patient developing treatment-related complications. Multivariate analysis was also performed with the same factors using Cox regression model. The occurrence of CDI was identified to be the most powerful independent variable (hazard ratio ¼ 20.146; 95% CI, 2.862-141.79; P ¼ 0.003). Multivariate analysis with the same factors was also performed using a stepwise logistic regression (Table 4) . CDI, the pretransplant disease status and VEGF cluster were significantly associated with the occurrence of NRM.
Discussion
These results suggest that low circulating levels of VEGF from pretransplant through to 2 weeks after the transplant are associated with the incidence of severe GVHD Xgrade III after allo-SCT. Patients with high VEGF levels were significantly protected from the development of NRM compared with those with low levels. Multivariate analysis revealed the VEGF cluster, CDI and pretransplant disease status to be independently associated with a higher incidence of NRM. Although the underlying pathophysiological mechanisms are unclear, the identification of a new biomarker that can be used to predict the transplant-related complications is of interest, particularly the life-threatening severe GVHD after allo-SCT. Refining a clinician's ability to predict the consequences based on the immune manifestation will help prevent GVHD and other transplant-related complications, as well as improving cancer treatment.
One of the earliest physiological responses to a tissue injury or infection is an increase in vascular permeability and blood flow to the affected area, which initiated by regional vasodilation followed by enhanced angiogenesis to facilitate the wound healing process. 21 VEGF is an endothelial cell-specific mitogen with an ability to promote angiogenesis. 22 In addition, it is intimately linked with the process of immune regulation. 23 These results are remarkable in that high circulating levels of VEGF were associated with the attenuated severity of acute GVHD leading to a reduced NRM. Within the cytokine network, the activation of the proinflammatory mediators is followed by the increased production of endogenous inhibitory molecules including antagonistic cytokines. Lunn et al. 11 reported that the serum VEGF levels were significantly higher in those with GVHD but the sera were collected at approximately at week þ 2. They did not show the circulating VEGF kinetics according to the clinical severity of acute GVHD. In this cohort, the serum VEGF levels decreased significantly on day þ 7 compared with day 0 and recovered on day þ 14. The release of pro-inflammatory cytokines early (day þ 7) after allo-SCT was previously reported to be significantly higher in patients with transplant-related complications than in uncomplicated patients. 24 Consequently, the elevated VEGF levels at day þ 14 might be associated with a burst of pro-inflammatory cytokines at day þ 7 throughout a network of cytokines, and have some influence on the occurrence of early complications caused by SIRS. However, we did not have measurements of VEGF on days À14 and À7. It cannot be excluded that serum VEGF levels were much higher before conditioning in all patients and that the low levels of circulating VEGF in the low VEGF group were caused by consumption of VEGF in tissues of those patients who experienced severe acute GVHD, infections or other complications leading to NRM.
It was previously demonstrated that among the complications occurring after allo-SCT, vascular endothelial damage and hypercytokinemia are involved in adult respiratory distress syndrome-like respiratory disorders, 25 TM, 26 acute GVHD 27 and CMV infection. 28 The interactions between VEGF and then transplant-related complications including CDI, hepatic VOD, TM, CMV infection and GVHD were examined according to the VEGF cluster. The incidence of complications except for the occurrence of acute GVHDXIII was similar in the two VEGF groups (Table 2) , which means that VEGF may play a major role Table 3 Univariate Cox regression analysis of the risk factors associated with nonrelapse mortality
Risk factors
Hazard ratio (95% CI) P-value in modulating the graft-versus-host reactions among the many manifestations of SIRS. In addition, the platelet recovery that was identified as an independent prognostic factor 29 was achieved more rapidly in patients with high VEGF levels. Recent evidence suggests that platelets are the main contributors to the serum VEGF. 30 Enhanced production of the BM platelet progenitors has been associated with endocytosis of circulating VEGF by platelets and/or megakaryocytes. 31 It was reported that thrombopoietin mimics hypoxia and controls the important genes required for VEGF. 32 The emerging recognition that a shift from a T-helper type 1 (Th1) to Th2 can downregulate the cell-mediated immune response as well as the inflammatory process should promote intense research on the role of these regulatory cytokines during the course of transplant-related complications. In antigen-induced inflammation, VEGF was preferentially produced by Th2 versus Th1 cells and is crucial in adaptive Th2 inflammation. 33 It is believed that dendritic cells (DC) are essential for inducing GVHD. 34 Human blood DC consist of plasmacytoid DC (PDC) and myeloid DC (MDC), both of which prime the immune responses after allo-SCT. High VEGF levels correlated with shifted PDC-induced T-cell polarization towards Th2 in vitro. 35 The observation of GVHD protection of circulating VEGF levels in our patients might be associated with a shift from MDC to PDC, and a shift from mainly Th1 to Th2 immune responses.
Based on the clinical data, the effect of blocking VEGF in vivo after allo-SCT was examined using a C57BL/6 (B6, H2 b )-C57BL/6 Â DBA2 (B6D2F1, H-2
) model for acute GVHD. A novel anti-VEGF peptide (dRK6) RRKRRR hexapeptide blocks the interaction between VEGF and its receptor. 36 dRK6 or control peptide was injected into the B6D2F1 recipients every other day for 2 weeks. There was a higher and more rapid mortality in the allo-SCT recipients injected with dRK6 than the controls. All the recipients showed the clinical features of acute GVHD at the time of death. In allogeneic recipients injected with dRK6 or control peptide, the serum VEGF levels (mean7s.d.) on day þ 14 were 26.373.2 pg/ml vs 31.372.0 pg/ml, respectively (P ¼ 0.32). Mice receiving syngeneic BMT (B6-B6) and dRK or control peptide showed 100% survival, thereby ruling out any nonspecific toxicity associated with the therapy (data not shown). The underlying mechanisms responsible for blocking the VEGF signals that exacerbate the severity of acute GVHD in the experimental allo-SCT model are currently under investigation.
The early identification of patients at risk of NRM is a relevant issue in allo-SCT. It has been shown that the C-reactive protein levels, the increase in the bilirubin and the blood urea nitrogen level at day þ 7 after the transplant increased the early NRM. 37, 38 In our patients, multivariate analysis revealed patients with CDI, an advanced disease and the VEGF cluster to have significantly higher risk of NRM. As the early posttransplant VEGF levels appear to be highly predictive of NRM, these results might provide a new parameter for selecting patients for clinical trials involving pre-emptive antiinflammatory treatments.
In conclusion, the serum VEGF levels early following allo-SCT were associated with the severity of acute GVHD and death caused by the complications associated with the transplant. These results suggest that VEGF might play a role in GVHD protection, and the early change in the VEGF level may be a surrogate marker for life-threatening acute GVHD.
